Roxadustat
Based on 64 publication(s) in Google Scholar
Roxadustat is an orally active hypoxia-inducible factor prolyl-hydroxylase (PHD) inhibitor (HIF-PHI) that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.92%
- CAS No.: 808118-40-3
- Formule: C19H16N2O5
- Masse moléculaire:352.34
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Roxadustat
More- Science. 2016 Apr 1;352(6281):54-61. [Abstract]
- Cell Metab. 2019 Nov 5;30(5):937-951.e5. [Abstract]
- Cell Metab. 2017 Jan 10;25(1):73-85. [Abstract]
- Ann Rheum Dis. 2024 Mar 19:ard-2023-224491. [Abstract]
- Mol Cell. 2021 May 6;81(9):2041-2052.e6. [Abstract]
- Nat Commun. 2025 Jan 24;16(1):985. [Abstract]
- Acta Pharm Sin B. 2025 Jun;15(6):3243-3258. [Abstract]
- Acta Pharm Sin B. 2025 Mar;15(3):1497-1513. [Abstract]
- Acta Pharm Sin B. 2023 Aug;13(8):3414-3424. [Abstract]
- Autophagy. 2021 Oct;17(10):2975-2990. [Abstract]
- J Biomed Sci. 2021 Nov 2;28(1):73. [Abstract]
- Cardiovasc Diabetol. 2025 Feb 7;24(1):67. [Abstract]
- Int J Biol Sci. 2024 Aug 6;20(11):4222-4237. [Abstract]
- Int J Biol Macromol. 2026 Feb;341(Pt 1):150328. [Abstract]
- Acta Pharmacol Sin. 2023 May;44(5):940-953. [Abstract]
- Acta Pharmacol Sin. 2023 Feb;44(2):308-320. [Abstract]
- Biomed Pharmacother. 2024 Apr:173:116342. [Abstract]
- Cell Rep. 2026 Jan 28;45(2):116922. [Abstract]
- Cell Rep. 2021 Apr 20;35(3):109020. [Abstract]
- Cell Rep. 2021 Aug 24;36(8):109607. [Abstract]
- EMBO Rep. 2022 Jan 5;23(1):e53054. [Abstract]
- Mol Ther Nucleic Acids. 2026 Mar 5;37(2):102886. [Abstract]
- Biochem Pharmacol. 2024 Sep 6:116522. [Abstract]
- J Ethnopharmacol. 2023 Sep 15:313:116533. [Abstract]
- Cells. 2025 Dec 23;15(1):31. [Abstract]
- Respir Res. 2024 Sep 28;25(1):351. [Abstract]
- Int J Mol Sci. 2026 Jun 18;27(12):5506. [Abstract]
- Int J Mol Sci. 2025 Jun 5;26(11):5410. [Abstract]
- Nanomaterials. 2022 Jan 3;12(1):163. [Abstract]
- Front Cell Dev Biol. 2021 Jul 2:9:690079. [Abstract]
- FASEB J. 2026 Jun 15;40(11):e71979. [Abstract]
- J Cell Mol Med. 2025 Jun;29(11):e70580. [Abstract]
- J Cell Mol Med. 2019 Jan;23(1):349-356. [Abstract]
- Oncol Rep. 2026 May;55(5):94. [Abstract]
- Sci Rep. 2026 Feb 24;16(1):7554. [Abstract]
- J Biol Chem. 2021 Jan-Jun:296:100397. [Abstract]
- Brain Res Bull. 2023 Dec:205:110822. [Abstract]
- Circ J. 2020 May 25;84(6):1028-1033. [Abstract]
- Stem Cells. 2023 Jan 30;41(1):77-92. [Abstract]
- Am J Physiol Gastrointest Liver Physiol. 2025 Mar 25. [Abstract]
- IUBMB Life. 2026 Apr;78(4):e70103. [Abstract]
- Environ Toxicol. 2024 Apr;39(4):2363-2373. [Abstract]
- Nitric Oxide. 2022 Jul 1:124:1-14. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- Diabetes Metab Syndr Obes. 2025 Nov 14:18:4211-4227. [Abstract]
- Drug Test Anal. 2021 Jun;13(6):1203-1215. [Abstract]
- Drug Test Anal. 2021 Feb;13(2):283-298. [Abstract]
- Tissue Cell. 2025 Aug:95:102828. [Abstract]
- ChemistrySelect. 2025 Mar 31.
- Physiol Res. 2023 Dec 29;72(S5):S587-S592. [Abstract]
- Nephrology (Carlton). 2023 Jan;28(1):60-71. [Abstract]
- Biol Pharm Bull. 2024;47(4):750-757. [Abstract]
- Biomed Chromatogr. 2021 Feb;35(2):e4970. [Abstract]
- Biotech Histochem. 2025 Mar 26:1-19. [Abstract]
- bioRxiv. 2026 Jun 10:2026.06.09.731212. [Abstract]
- Res Sq. 2026 Jun 18.
- Patent. US20250262229A1.
- Cyberleninka. 2025.
- Ghent University. 2024.
- bioRxiv. 2024 May 30:2024.05.29.595538. [Abstract]
- bioRxiv. 2023 Nov 2.
- Preprints. 2023 Nov 27, 2023111678.
- bioRxiv. 2023 Nov 1:2023.10.31.564956. [Abstract]
- Patent. US20180263995A1.
-
WB
-
IF
-
WB
Activité biologique
Hypoxia-inducible factor prolyl-hydroxylase[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HK-2 | IC50 |
0.01 μM
Compound: 153
|
Downregulation of BNIP3 expression in human HK-2 cells incubated for 6 hrs by Western blot analysis
Downregulation of BNIP3 expression in human HK-2 cells incubated for 6 hrs by Western blot analysis
|
[PMID: 38295689] |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:12-week female C57BL/6 mice[2]
-
Dosage:50 mg/kg
-
Administration:Intraperitoneal injection; daily for 7 days
-
Result:Protected the survival of motor neurons and improved recovery from spinal cord injury.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 808118-40-3
-
Appearance Solid
-
Masse moléculaire 352.34
-
Formule C19H16N2O5
-
Color Light yellow to green yellow
-
SMILES
O=C(O)CNC(C1=C(O)C2=C(C(C)=N1)C=C(OC3=CC=CC=C3)C=C2)=O
-
Synonyms
FG-4592
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (64)
-
Journal Impact Factor
-
Most Recent
-
Science
2016 Apr 1;352(6281):54-61. PMID: 26917594
Roxadustat purchased from MedChemExpress. Usage Cited in: Science. 2016 Apr 1;352(6281):54-61. [Abstract]
FG-4592 causes normoxic stabilization of HIF1α and rewires energy metabolism. Immunoblot showing HIF1α ± RC inhibition with antimycin or oligomycin, ± FG-4592 under normoxia (21% O2) or hypoxia (1% O2). RC inhibition prevents HIF1α stabilization during hypoxia. FG-4592 administration overcomes this paradox and stabilizes HIF1α even during normoxia. Immunoblot is representative of independent experiments done in duplicate in HT-29 cells.
-
Cell Metab
Adipocyte Hypoxia-Inducible Factor 2α Suppresses Atherosclerosis by Promoting Adipose Ceramide Catabolism. [Abstract]2019 Nov 5;30(5):937-951.e5. PMID: 31668872 -
Cell Metab
Reciprocal Regulation between the Circadian Clock and Hypoxia Signaling at the Genome Level in Mammals. [Abstract]2017 Jan 10;25(1):73-85. PMID: 27773697 -
Ann Rheum Dis
Expression of HIF1α in intestinal epithelium restricts arthritis inflammation by inhibiting RIPK3-induced cell death machinery. [Abstract]2024 Mar 19:ard-2023-224491. PMID: 38503474 -
Mol Cell
Physiological hypoxia restrains the senescence-associated secretory phenotype via AMPK-mediated mTOR suppression. [Abstract]2021 May 6;81(9):2041-2052.e6. PMID: 33823141 -
Nat Commun
Lysosomes finely control macrophage inflammatory function via regulating the release of lysosomal Fe2+ through TRPML1 channel. [Abstract]2025 Jan 24;16(1):985. PMID: 39856099 -
Acta Pharm Sin B
A photodynamic nanohybrid system reverses hypoxia and augment anti-primary and metastatic tumor efficacy of immunotherapy. [Abstract]2025 Jun;15(6):3243-3258. PMID: 40654337 -
Acta Pharm Sin B
Ginsenoside CK targets PHD2 to prevent platelet adhesion and enhance blood circulation by modifying the three-dimensional arrangement of collagen. [Abstract]2025 Mar;15(3):1497-1513. PMID: 40370536 -
Acta Pharm Sin B
A new class of potent liver injury protective compounds: Structural elucidation, total synthesis and bioactivity study. [Abstract]2023 Aug;13(8):3414-3424. PMID: 37655332 -
Autophagy
Inhibiting NLRP3 inflammasome attenuates apoptosis in contrast-induced acute kidney injury through the upregulation of HIF1A and BNIP3-mediated mitophagy. [Abstract]2021 Oct;17(10):2975-2990. PMID: 33345685 -
J Biomed Sci
Transforming growth factor-β1 decreases erythropoietin production through repressing hypoxia-inducible factor 2α in erythropoietin-producing cells. [Abstract]2021 Nov 2;28(1):73. PMID: 34724959 -
Cardiovasc Diabetol
Roxadustat improves diabetic myocardial injury by upregulating HIF-1α/UCP2 against oxidative stress. [Abstract]2025 Feb 7;24(1):67. PMID: 39920720 -
Int J Biol Sci
IL-6 signaling accelerates iron overload by upregulating DMT1 in endothelial cells to promote aortic dissection. [Abstract]2024 Aug 6;20(11):4222-4237. PMID: 39247821 -
Int J Biol Macromol
MgFe-LDH nanocomposites incorporated into gelatin methacryloyl /hyaluronic acid methacrylated hydrogels for controlled drug release: Synergistic regulation of angiogenesis-osteogenesis for bone regeneration. [Abstract]2026 Feb;341(Pt 1):150328. PMID: 41548783 -
Acta Pharmacol Sin
Inhibiting von Hippel‒Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism. [Abstract]2023 May;44(5):940-953. PMID: 36357669 -
Acta Pharmacol Sin
Roxadustat alleviates nitroglycerin-induced migraine in mice by regulating HIF-1α/NF-κB/inflammation pathway. [Abstract]2023 Feb;44(2):308-320. PMID: 35948752 -
Biomed Pharmacother
Prolyl hydroxylase inhibitor FG-4592 alleviates neuroinflammation via HIF-1/BNIP3 signaling in microglia. [Abstract]2024 Apr:173:116342. PMID: 38430635 -
Cell Rep
α-Ketoglutarate couples cellular metabolism to developmental growth via hydroxylation-dependent degradation of Yorkie. [Abstract]2026 Jan 28;45(2):116922. PMID: 41610010 -
Cell Rep
Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. [Abstract]2021 Apr 20;35(3):109020. PMID: 33852916 -
Cell Rep
Macrophage HIF-2α suppresses NLRP3 inflammasome activation and alleviates insulin resistance. [Abstract]2021 Aug 24;36(8):109607. PMID: 34433035 -
EMBO Rep
Metabolic resistance to the inhibition of mitochondrial transcription revealed by CRISPR-Cas9 screen. [Abstract]2022 Jan 5;23(1):e53054. PMID: 34779571 -
Mol Ther Nucleic Acids
A transferable SARS-CoV-2 IRES module enables dual translation initiation for enhanced antigen expression in COVID-19 mRNA vaccines. [Abstract]2026 Mar 5;37(2):102886. PMID: 41883582 -
Biochem Pharmacol
2024 Sep 6:116522. PMID: 39245394 -
J Ethnopharmacol
Systems pharmacology reveals the mechanism of Astragaloside IV in improving immune activity on cyclophosphamide-induced immunosuppressed mice. [Abstract]2023 Sep 15:313:116533. PMID: 37100262 -
Cells
Hypoxia Affects Stem Cell Fate in Patient-Derived Ileum Enteroids in a HIF-1α-Dependent Manner. [Abstract]2025 Dec 23;15(1):31. PMID: 41511315 -
Respir Res
Localized delivery of therapeutics impact laryngeal mechanics, local inflammatory response, and respiratory microbiome following upper airway intubation injury in swine. [Abstract]2024 Sep 28;25(1):351. PMID: 39342180 -
Int J Mol Sci
Roxadustat Inhibits Osteoclast Differentiation and Function by Disrupting Cell Cycle Exit. [Abstract]2026 Jun 18;27(12):5506. PMID: 42353219 -
Int J Mol Sci
Pharmacological HIF-PH Inhibition Suppresses Myoblast Differentiation Through Continued HIF-1α Stabilization. [Abstract]2025 Jun 5;26(11):5410. PMID: 40508217 -
Nanomaterials
2022 Jan 3;12(1):163. PMID: 35010112 -
Front Cell Dev Biol
Transcription-Based Multidimensional Regulation of Fatty Acid Metabolism by HIF1α in Renal Tubules. [Abstract]2021 Jul 2:9:690079. PMID: 34277635 -
FASEB J
Roxadustat Ameliorates Thoracic Aortic Dissection by Activating HIF-1α-Mediated Mitophagy to Inhibit Ferroptosis. [Abstract]2026 Jun 15;40(11):e71979. PMID: 42201682 -
J Cell Mol Med
Inhibitors of p53 Apoptosis-Stimulating Protein Mitigate Acute Kidney Injury by Modulating the HIF-1α/SLC7A11 Pathway to Suppress Ferroptosis. [Abstract]2025 Jun;29(11):e70580. PMID: 40492946 -
J Cell Mol Med
2019 Jan;23(1):349-356. PMID: 30334352
Roxadustat purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Jan;23(1):349-356. [Abstract]
FG-4592 increases level of HIF-1α and regulates apoptosis-related proteins in AHH-1. The effects of FG-4592 on HIF1-α are detected using Western Blot. Level of HIF-1α is measured at different time points after the treatment of FG-4592 (A). Cell lysate is obtained at 6 h after irradiation and used to evaluate the regulation of FG-4592 on apoptosis-related molecules. Apoptosis promoting molecules (c-caspase3 and cyt-c) are downregulated and molecules that inhibit apoptosis are up-regulated by FG-4
Roxadustat purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2019 Jan;23(1):349-356. [Abstract]
FG-4592 mitigates radiation-induced DNA injuries. AHH-1 cells pretreated with or without FG-4592 are exposed to 6 Gy irradiation and γ-H2AX assay is used to determine DNA damages at 0, 0.5, 2 h after irradiation.
-
Oncol Rep
Depleting HIF‑1α attenuates the progression of osteosarcoma, but tumorigenicity is sustained through HIF‑independent pathways. [Abstract]2026 May;55(5):94. PMID: 41823542 -
Sci Rep
Targeted hypoxia-inducible factor 1-alpha (HIF1A) stabilization during in vitro maturation of bovine cumulus-oocyte complexes increases blastocyst rates. [Abstract]2026 Feb 24;16(1):7554. PMID: 41735350 -
J Biol Chem
Development of a colorimetric α-ketoglutarate detection assay for prolyl hydroxylase domain (PHD) proteins. [Abstract]2021 Jan-Jun:296:100397. PMID: 33571527 -
Brain Res Bull
The effects of prolyl hydroxylase inhibition during and post, hypoxia, oxygen glucose deprivation and oxidative stress, in isolated rat hippocampal slices. [Abstract]2023 Dec:205:110822. PMID: 37984622 -
Circ J
2020 May 25;84(6):1028-1033. PMID: 32213720 -
Stem Cells
2023 Jan 30;41(1):77-92. PMID: 36208284 -
Am J Physiol Gastrointest Liver Physiol
Hypobaric hypoxia exposure impairs colonic goblet cell subpopulation via the HIF-1α signaling pathway. [Abstract]2025 Mar 25. PMID: 40132123 -
IUBMB Life
HIF Signalling Modulates p53/miR-145-5p Axis in Hypoxia-Driven Tumorigenesis of HepG2 Tumourspheres. [Abstract]2026 Apr;78(4):e70103. PMID: 42015891 -
Environ Toxicol
2024 Apr;39(4):2363-2373. PMID: 38156404 -
Nitric Oxide
Activation of transcription factor HIF inhibits IL-1β-induced NO production in primary cultured rat hepatocytes. [Abstract]2022 Jul 1:124:1-14. PMID: 35460897 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
Diabetes Metab Syndr Obes
PEDF Alleviates Diabetic Renal Fibrosis by Degrading Kidney Ectopic Fat Deposition and Inhibiting Metabolic Reprogramming of Renal Tubular Epithelial Cells. [Abstract]2025 Nov 14:18:4211-4227. PMID: 41262465 -
Drug Test Anal
Identification of Hypoxia-inducible factor (HIF) stabilizer roxadustat and its possible metabolites in thoroughbred horses for doping control. [Abstract]2021 Jun;13(6):1203-1215. PMID: 33569900 -
Drug Test Anal
High-throughput liquid chromatography tandem mass spectrometry assay as initial testing procedure for analysis of total urinary fraction. [Abstract]2021 Feb;13(2):283-298. PMID: 32852861 -
Tissue Cell
Roxadustat pre-conditioning and cyclic uniaxial stretching improve tenogenic differentiation potential of human adipose derived mesenchymal stromal cells. [Abstract]2025 Aug:95:102828. PMID: 40086111 -
-
Physiol Res
Hypoxia-inducible factors activator, roxadustat, increases pulmonary vascular resistance in rats. [Abstract]2023 Dec 29;72(S5):S587-S592. PMID: 38165762 -
Nephrology (Carlton)
2023 Jan;28(1):60-71. PMID: 36217796 -
Biol Pharm Bull
Clinical Analysis and in Vitro Correlation of BCRP-Mediated Drug-Drug Interaction in the Gastrointestinal Tract. [Abstract]2024;47(4):750-757. PMID: 38556260 -
Biomed Chromatogr
Automated sample preparation for the detection and confirmation of hypoxia-inducible factor stabilizers in urine. [Abstract]2021 Feb;35(2):e4970. PMID: 32840903 -
Biotech Histochem
Hypoxia-induced HIF-1α accumulation promotes superior tenogenic differentiation potential of human adipose-derived mesenchymal stromal cells. [Abstract]2025 Mar 26:1-19. PMID: 40135543 -
bioRxiv
Epigenetic de-repression of basal cell metaplasia in aging AT2 cells is a risk factor for idiopathic pulmonary fibrosis (IPF). [Abstract]2026 Jun 10:2026.06.09.731212. PMID: 42327275 -
-
-
-
-
bioRxiv
2024 May 30:2024.05.29.595538. PMID: 38853866 -
-
-
bioRxiv
2023 Nov 1:2023.10.31.564956. PMID: 37961409 -
Solvant et solubilité
DMSO : 100 mg/mL (283.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.10 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (14.19 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Provenzano R, et al. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving MaintenanceHemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. Am J Kidney Dis. 2016 Jun;67(6):912-24. [Content Brief]
[2]. Wu K, et al. Stabilization of HIF-1α by FG-4592 promotes functional recovery and neural protection in experimental spinal cord injury. Brain Res. 2016 Feb 1;1632:19-26. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8382 mL | 14.1908 mL | 28.3817 mL | 70.9542 mL |
| 5 mM | 0.5676 mL | 2.8382 mL | 5.6763 mL | 14.1908 mL | |
| 10 mM | 0.2838 mL | 1.4191 mL | 2.8382 mL | 7.0954 mL | |
| 15 mM | 0.1892 mL | 0.9461 mL | 1.8921 mL | 4.7303 mL | |
| 20 mM | 0.1419 mL | 0.7095 mL | 1.4191 mL | 3.5477 mL | |
| 25 mM | 0.1135 mL | 0.5676 mL | 1.1353 mL | 2.8382 mL | |
| 30 mM | 0.0946 mL | 0.4730 mL | 0.9461 mL | 2.3651 mL | |
| 40 mM | 0.0710 mL | 0.3548 mL | 0.7095 mL | 1.7739 mL | |
| 50 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL | 1.4191 mL | |
| 60 mM | 0.0473 mL | 0.2365 mL | 0.4730 mL | 1.1826 mL | |
| 80 mM | 0.0355 mL | 0.1774 mL | 0.3548 mL | 0.8869 mL | |
| 100 mM | 0.0284 mL | 0.1419 mL | 0.2838 mL | 0.7095 mL |